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One long standing aspect of microglia biology was never questioned; their involvement
in brain disease. Based on morphological changes (retracted processes and amoeboid
shape) that inevitably occur in these cells in case of damage in the central nervous system,
microglia in the diseased brain were called “activated.” Because “activated” microglia
were always found in direct neighborhood to dead or dying neuron, and since it is known
now for more than 20 years that cultured microglia release numerous factors that are able
to kill neurons, microglia “activation” was often seen as a neurotoxic process. From an
evolutionary point of view, however, it is difﬁcult to understand why an important, mostly
post-mitotic and highly vulnerable organ like the brainwould host numerous potential killers.
This review is aimed to critically reconsider the term microglia neurotoxicity and to discuss
experimental problems around microglia biology, that often have led to the conclusion that
microglia are neurotoxic cells.
Keywords: microglia, neuroprotection, mouse models, innate immunity, CX3CR1, microglia depletion
INTRODUCTION
Microglia research has intensiﬁed enormously in the last decade,
and many surprising ﬁndings have been published. However,
microglia still rank among the most mysterious cells of the brain
and only recent results have begun to provide answers to the most
basic questions in microglial biology, for example the origin of
these cells, or the fact that microglia are not replaced by periph-
eral monocytes/macrophages in the healthy situation (Ajami et al.,
2007; Ginhoux et al., 2010; Kierdorf et al., 2013). Moreover, it has
become clear that “resting” microglia are by no means just idle
cells (Nimmerjahn et al., 2005; Sierra et al., 2010; Tremblay et al.,
2010; Paolicelli et al., 2011; Vinet et al., 2012) and there is good
evidence to suggest that microglia are not only important in brain
pathology but also play important roles in the healthy brain (Wake
et al., 2009; Sierra et al., 2010; Tremblay et al., 2010; Paolicelli et al.,
2011; Schafer et al., 2012). Thus, the general and simple con-
cept of microglia “activation” is now questionable (see for recent
reviews: Hanisch and Kettenmann, 2007; Colton, 2009; Ransohoff
and Perry, 2009; Yong and Rivest, 2009; Graeber, 2010; Parkhurst
and Gan, 2010; Ransohoff and Cardona, 2010; Kettenmann et al.,
2011; Prinz et al., 2011; Tremblay et al., 2011; Aguzzi et al., 2013;
Kettenmann et al., 2013). One long standing aspect of microglia
biology, however, has never been challenged; namely, their involve-
ment in brain disease, which was proposed many decades ago.
This assumption was ﬁrst based on morphological data, whereby
ramiﬁed microglia in the healthy brain were described as “rest-
ing,” the rounded,macrophage-likemicroglia in the diseased brain
were designated as “activated” microglia. Later it was shown that
“activated” microglia sometimes express potential harmful sub-
stances, which led to the suggestion that these cells are detrimental
during brain disease. On top of this, numerous cell culture exper-
iments, most of which involved lipopolysaccharide (LPS)-treated
microglia that have the potential to kill neurons, have further
corroborated the assumption that “activated” microglia are neu-
rotoxic cells (see for recent reviews: Block et al., 2007). However,
from an evolutionary point of view it is difﬁcult to understandwhy
a highly sensitive, but otherwise long-lived, post-mitotic organ like
the brainwould serve as a host to such a largenumberof potentially
toxic cells.
This review therefore aims to critically reconsider the com-
mon view that “activated” microglia are neurotoxic cells, and
to highlight studies in which the role of microglia in vivo was
speciﬁcally targeted, often revealing a protective function of these
cells.
MICROGLIA IN VITRO STUDIES
The ﬁrst direct evidence concerning microglia as neurotoxic
cells was published some 20 years ago (see for example: Boje
and Arora, 1992; Chao et al., 1992). These experiments utilized
standard microglia cultures (shake-off microglia from cultured
neonatal brain homogenate) that were stimulated with rather
high concentrations of single or combined pro-inﬂammatory
stimuli such as LPS, interferon-gamma (IFN-γ), or tumor necro-
sis factor-α (TNF-α). These cells (or the resulting supernatant)
were transferred to plates containing cultured neurons, and incu-
bated for some time before neuronal survival was assessed (Boje
and Arora, 1992; Chao et al., 1992). Ever since these pioneering
experiments were performed, numerous variations of this exper-
imental paradigm have identiﬁed a plethora of toxic microglial
secretory products and/or detrimental microglia functions that
obviously add weight to the notion that microglia are neuro-
toxic cells (see for recent examples: Lehnardt et al., 2008; Pais
et al., 2008; Levesque et al., 2010; Burguillos et al., 2011; Gao
et al., 2011). Thus, from the numerous papers that have inves-
tigated the inﬂuence of in vitro microglia on the survival of
neurons, the majority has described a detrimental microglia
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role. Fewer studies have also found a neuroprotective function
of cultured microglia showing that not all functions of cultured
microglia are detrimental for neurons (see for recent review:
Polazzi and Monti, 2010).
Cell culture experiments, however, should be approached with
caution, especially when highly sensitive and reactive cells such
as microglia are used. Standard cultured microglia have at least
threemajor disadvantages: First, since standard culturedmicroglia
are derived from the neonatal brain, these cells have missed the
potential maturation process that occurs in vivo. Second, cultured
microglia are grown in serum-containing (usually 10%) medium,
whereas in vivo microglia normally never come in contact with
serum components. Third, nowadays it is also very well known
that in vivo microglia are kept under constant restraint by a vari-
ety inhibitory inputs such as CX3CL1, CD200, CD22, or CD172
(see for review: Biber et al., 2007; Ransohoff and Cardona, 2010;
Prinz et al., 2011), which, of course, is not the case in culture.
Indeed, the genetic removal of even just one of these inhibitory
factors in animal models dramatically changes the reaction proﬁle
of microglia, often causing overshooting microglia reactions and
sometimes even toxic microglia responses (Hoek et al., 2000; Car-
dona et al., 2006); therefore, it is very likely that the complete lack
of normal inhibition has a dramatic inﬂuence on the reactivity of
cultured microglia.
Despite the caveats associated with studying microglial func-
tion in vitro, there is surprisingly little research regarding the
question of whether cultured microglia can be reliably com-
pared to their in vivo counterparts. One such report by Boucsein
et al. (2000) investigated the electrophysiological properties of
microglia by comparing cultured (with or without LPS treatment)
and ramiﬁed microglia in acute brain slice preparations. It was
found that ramiﬁed microglia barely display membrane currents,
in stark contrast to primary cultured microglia, which elicited
inward and outward rectifying currents (depending on LPS treat-
ment) that were similar to those found in cultured macrophages
(Boucsein et al., 2000). More recently, Schmid et al., 2009 com-
pared mRNA expression proﬁles between cultured microglia and
alveolar macrophages stimulated with LPS/IFN-γ and microglia
rapidly isolated from the brain of LPS/IFN-γ treated animals.
This study also reported that cultured microglia and macrophages
are much more alike than the microglia that have been acutely
derived from brain tissue (Schmid et al., 2009). Recently, a simi-
lar comparative analysis was performed for post-mortem human
microglia and macrophages derived from the choroid plexus
(Melief et al., 2012). These authors not only provided con-
vincing evidence for major differences in surface marker and
mRNA expression pattern between brain-derived microglia and
macrophages, they further showed that acutely isolated microglia
are not able to respond to LPS stimulation, most likely because
these cells lack CD14 (Melief et al., 2012). It is yet not known
whether this lack of CD14 and LPS response is due to the isola-
tion technique used in the study. However, overnight incubation
in culture increased CD14 levels and rendered the cells sensi-
tive to LPS treatment, again suggesting that growing microglia
in culture can have a tremendous inﬂuence on the reactivity
of these cells (Melief et al., 2012). These results strongly impli-
cate that cultured microglia share few similarities with their in
vivo counterparts, which leads to the conclusion that in vitro
evidence concerning microglia should be interpreted with the
utmost caution when extrapolating data into the context of the
brain.
NEURONAL LOSS AND THE PRESENCE OF AMOEBOID
MICROGLIA: CHICKEN OR EGG?
Histological studies by Del Rio-Hortega identiﬁed microglia
almost a century ago (see Kettenmann et al., 2011 for an excel-
lent overview on microglia history) and even back in the early
days of microglia research, the potential importance of these cells
in brain disease was already been recognized. Indeed, these sem-
inal histological studies on microglia morphology also gave rise
to the concept of microglia “activation,” which states that ram-
iﬁed microglia in the healthy brain are in a resting state, and
that upon any potential danger signal these cells morph into
an amoeboid or macrophage-like shape. Because the complexity
of this morphological transition is limited, microglia responses
were generally seen as graded and stereotypic (see for review:
Kettenmann et al., 2011). In other words it was more or less
believed that microglia always had the same role once they become
amoeboid. Numerous in vivo reports have concluded that amoe-
boid microglia can potentially confer neurotoxicity by expressing
substances (that are toxic in vitro) such as pro-inﬂammatory
cytokines (Blais and Rivest, 2004; Xie et al., 2004; Allan et al.,
2005; Kim and de Vellis, 2005; Walker and Lue, 2005). Other
reports usedminocycline (a potentialmicroglia inhibitor) or other
anti-inﬂammatory drugs to ameliorate damage in different mod-
els of brain diseases and since at the same time a decreased
morphological transition of microglia was observed these results
were often discussed in favor of a neurotoxic role of amoeboid
microglia (see for example: Yrjänheikki et al., 1998; He et al.,
2001; Tikka et al., 2001; Kriz et al., 2002; Hunter et al., 2004;
Fan et al., 2005).
However, it could very well be that the morphological transi-
tion of microglia is the result rather than the cause of neuronal
damage, as was shown in a model of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and methamphetamine (METH)-
induced neurotoxicity (O’Callaghan et al., 2008). In addition, the
fact that microglia may undergo morphological transition in the
absence neuronal loss is often disregarded. For example, although
the injection of LPS in vivo causes rapid morphological transition
of microglia, yet it does not induce massive neuronal death, except
when injected into the substantia nigra (Kim et al., 2000; Nadeau
and Rivest, 2002, 2003). Moreover, it has been known for more
than 10 years that microglia in the spinal cord become amoe-
boid in response to peripheral nerve injury, which is important
for the development of neuropathic pain. However, despite the
presence of activated microglia, neuronal loss is not a hallmark of
neuropathic pain.
Taken together,we think that there is a bias in the ﬁeld regarding
the functionof amoeboidmicroglia. The temporal and spatial rela-
tionship between amoeboidmicroglia-like cells (see next chapters)
and dead or dying neurons -which inevitably occurs in case of neu-
ronal damage- is often seen as indication for a neurotoxic role of
microglia. Such correlation, of course, does not allow conclusions
about causality.
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TARGETING MICROGLIA IN MOUSE MODELS OF DISEASE
Using an experimental approach to understand microglial func-
tion is a challenging task and as a result most studies, although
carefully performed, did not speciﬁcally target microglia. In
numerous studies is a microglia reaction induced by exoge-
nous application of pro-inﬂammatory molecules (injection of
IL-1, TNFα, LPS, and others) that unleash an uncontrollable
immune response, not only in the brain (which also potentially
involves astrocytes, oligodendrocytes, endothelial cells, perivas-
cular macrophages, and neurons), but also most likely causes an
immune response in the periphery. The second-generation tetra-
cycline minocycline is often referred to as a speciﬁc inhibitor of
microglia (see for example: Raghavendra et al., 2003; Ledeboer
et al., 2005; Mika et al., 2007; Osikowicz et al., 2009). However, it
should be kept in mind that minocycline is much less speciﬁc than
often stated, as it clearly affects peripheral macrophages (Dun-
ston et al., 2011), and T cells (Szeto et al., 2011), and can have
a direct inﬂuence on the survival of neuronal cell lines and cul-
tured neurons (Hashimoto and Ishima, 2010; Huang et al., 2010;
Schildknecht et al., 2011; Ossola et al., 2012), thus, numerous
microglia-independent effects of minocycline have been published
(Hughes et al., 2004). Moreover, it was reported that the microglia
reaction in response to facial nerve injury is unchanged in the pres-
ence of even high concentrations of minocycline (Fendrick et al.,
2005). Similarly, other anti-inﬂammatory drugs are not speciﬁc
for microglia either; for example, the neuroprotective effect of the
anti-inﬂammatory compound triﬂusal was found not to depend
on the presence of microglia (Montero Domínguez et al., 2009). It
can thus be concluded that more speciﬁc methods are needed to
address microglia function.
MICROGLIA VS. OTHER PERIPHERAL
MONOCYTES/MACROPHAGES
THE PROBLEM OF IDENTIFICATION
Microglia are derived from early myeloid precursor cells
that appear in the yolk sac before major vascularization or
hematopoiesis occurs in the developing embryo (Sorokin et al.,
1992; Alliot et al., 1999; Herbomel et al., 2001; Ginhoux et al.,
2010; Mizutani et al., 2012). Strikingly, it was found that microglia
stem from primitive erythromyeloid progenitor cells that develop
via a special program into mature microglia, and most impor-
tantly that these cells form a stable self-contained population that
is not replaced by peripheral monocytes in the unchallenged brain
(Kierdorf et al., 2013; Neumann and Wekerle, 2013).
While microglia can be easily identiﬁed in the healthy brain,
this changes under pathological conditions in which peripheral
monocytes/macrophages enter the brain. Despite the fact that
microglia and peripheral monocytes/macrophages have differ-
ent developmental origins, both cell populations share many
properties. The expression of general innate pattern recognition
receptors such as Toll-like receptors (TLR), nucleotide-binding
oligomerization domain (NOD)-lime receptors (NLR), or com-
plement receptors are common to both microglia and peripheral
monocytes/macrophages, as is the ability to secrete a whole
variety of different cytokines (pro- and anti-inﬂammatory),
growth factors, chemokines, reactive oxygen, and nitrogen species
(Kettenmann et al., 2011; Jung and Schwartz, 2012). The lack
of reliable microglia-speciﬁc markers makes it very difﬁcult
both to discriminate between microglia and peripheral mono-
cytes/macrophages, to allocate functions to either cell type (Jung
and Schwartz, 2012). This difﬁculty may have added confusion
to the question whether or not microglia in the diseased brain
are neurotoxic cells: an example here is the chemokine receptor
CCR2. On one hand there are various reports in which CCR2
expressing cells are suggested to be microglia (Abbadie et al., 2003;
Zhang et al., 2007; Fernández-López et al., 2012) or described
as microglia/macrophages (Yao and Tsirka, 2012) or referred to
as amoeboid microglia cells (Deng et al., 2009). Often CCR2 is
discussed to be an important receptor for the recruitment of
microglia to injured brain areas (El Khoury et al., 2007; Zhang
et al., 2007; Deng et al., 2009; Raber et al., 2013) and the inhi-
bition or lack of CCR2 signaling is related to improved disease
outcome (Abbadie et al., 2003; Dimitrijevic et al., 2007; Zhang
et al., 2007; Fernández-López et al., 2012; Yao and Tsirka, 2012)
implicating that CCR2-expressing microglia at least contribute to
disease progression.
On the other hand there is convincing evidence from differ-
ent transgenic mouse models and bone-marrow transplantation
experiments that microglia do not express CCR2 in the healthy
or diseased brain (Mildner et al., 2007; Jung et al., 2009; Saederup
et al., 2010; Mizutani et al., 2012), moreover mouse microglia lack
the mRNA for CCR2 (Zuurman et al., 2003; Olah et al., 2012).
In bone-marrow transplantation experiments it was shown that
the response of endogenous microglia to stroke was not affected
in CCR2 deﬁcient animals, showing that CCR2 is not regulating
microglia responses here (Schilling et al., 2009a,b). In these studies
it was shown that the inﬁltration of peripheral monocytes into the
brainwas greatly reduced,which is in agreementwith other reports
clearly showing that peripheral monocytes require CCR2 in order
to invade the diseased central nervous system (CNS; Mildner et al.,
2007; Schilling et al., 2009a,b; Prinz and Priller, 2010; Prinz and
Mildner, 2011; Mizutani et al., 2012).
Thus CCR2 in the brain should be regarded as marker
of peripheral monocytes/macrophages making it questionable
whether the published (mostly detrimental) effects of CCR2
expressing cells can be allocated to microglia. CCR2 most likely
is not the only example in this respect, showing that without a
proper identiﬁcation it is not possible to draw conclusions about
microglia function.
HOW TO TELL THEM APART?
One way to discriminate between monocytes/macrophages and
microglia is offered by ﬂow cytometry analysis [(ﬂuorescence
assisted cell sorting (FACS)] of acutely isolated cell prepara-
tions from the diseased brain using CD11b and CD45 antibodies.
Although monocytes/macrophages and microglia are both posi-
tive for CD11b and CD45, microglia can be identiﬁed by their
relatively low expression levels of CD45 (“CD45dim”) compared
to those of peripheral monocytes/macrophages (“CD45high”).
Thus microglia and monocytes/macrophages appear as separate
cell populations in FACS analysis (Sedgwick et al., 1998; de Haas
et al., 2007, 2008; Remington et al., 2007).
We used such a FACS-based identiﬁcation approach in a mouse
model of cuprizone-induced loss of oligodendrocytes, whereby
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microglia were speciﬁcally isolated from the corpus callosum of
mice before cuprizone treatment, during demyelination and after
remyelination (Olah et al., 2012). Thus, pure preparations of ram-
iﬁed microglia (healthy controls), amoeboid microglia (peak of
demyelination) and microglia returning to the quiescent state
(2weeks post-remyelination)were subjected to genome-wide gene
expression analysis. One aim of this study was to describe the two-
sides of microglia activity, based on our expectation of ﬁnding
a pro-inﬂammatory proﬁle in the amoeboid microglia isolated
during the demyelination phase, and a more anti-inﬂammatory
expression proﬁle in microglia isolated from the corpus callo-
sum during the remyelination period. To our surprise, we did
not ﬁnd any evidence for a double-edged function of microglia
during the disease course in this model. Instead we observed a
microglial phenotype that supported remyelination at the onset
of demyelination, a function which persisted throughout the
remyelination process (Olah et al., 2012). Our data showed that
microglia are involved in the phagocytosis of myelin debris and
apoptotic cells during demyelination (Olah et al., 2012). Further-
more, microglia displayed cytokine and chemokine expression
proﬁles that were associated with the activation and recruitment
of endogenous oligodendrocyte precursor cells to the lesion site, as
well as the delivery of trophic support during remyelination (Olah
et al., 2012). In other words, although corpus callosal microglia
displayed an amoeboid morphology under demyelinating condi-
tions, these cells expressed proteins that, rather than potentially
contributing to oligodendrocyte death, actually initiated a repair
response, even during the early onset phase of the disease.
Another way to discriminate peripheral monocytes/macro-
phages vs. endogenous microglia are bone-marrow transplan-
tation or parabiosis experiments. Both have been utilized in
experimental allergic encephalomyelitis (EAE) and it was observed
that peripheral myeloid cells utilize CCR2 in order to invade the
diseased brain and that an inhibition of this invasion resulted
in a signiﬁcantly diminished EAE disease course, leading the
authors to conclude that peripheral monocytes/macrophages but
not resident microglia cells are responsible for disease progres-
sion in EAE (Mildner et al., 2009; Ajami et al., 2011). Using
bone-marrow transplantation and different genetic models it
was further demonstrated that in acute spinal cord injury,
endogenous microglia also differ functionally from invading
peripheral monocytes/macrophages (see for review: Jung and
Schwartz, 2012).
Thus there are various studies that convincingly demonstrate
that peripheral monocytes/macrophages may have signiﬁcantly
different functions compared to endogenous microglia in the dis-
eased brain. Interestingly, a more speciﬁc analysis of microglia
(as discussed above) often (but not always, see Jung and Schwartz,
2012) revealed beneﬁcial, or at least non-toxicmicroglia responses.
LACK OF CX3CR1 OR CD200r IN MICROGLIA
As mentioned above, nowadays it is clear that microglia in the
brain are under constant restraint, particularly because they specif-
ically express receptors for a variety of inhibitory factors that are
constitutively expressed in the brain, mostly by neurons (Biber
et al., 2007; Ransohoff and Perry, 2009). The most prominent
ligand-receptor pairs in this respect are CX3CL1-CX3CR1 and
CD200-CD200r. Regarding the CX3CR1-CX3CL1 axis, one of the
most used mouse model in microglia research is the CX3CR1-
EGFP mouse line in which all microglia are green ﬂuorescent
protein (GFP)-positive (Jung et al., 2000). This mouse line, has
since contributed enormously to our current understanding of
microglia biology, and CX3CR1-deﬁcient homozygotes have been
used extensively to study the role of CX3CR1 in various models
of brain disease. Indeed, the consequences of CX3CR1 deletion
in microglia largely depends on the mouse model used (see for
extensive review: Prinz et al., 2011; Ransohoff and Prinz, 2013;
Wolf et al., 2013); however, the overall idea at the moment is that
a lack of CX3CR1 leads to the “hyperactivity” of microglia in the
diseased brain, thereby unleashing potential neurotoxic properties
(Wolf et al., 2013). Accordingly, administration of CX3CL1 into
the brain causes neuroprotection in experimental stroke and two
models of Parkinsons disease (Cipriani et al., 2011; Pabon et al.,
2011; Morganti et al., 2012) Similarly, removing the inhibitory
input that is normally modulated by CD200 [i.e., as in CD200r
knockout (KO) mice] reportedly promotes microglial morpho-
logical transition even in the healthy brain (Hoek et al., 2000) and
leads to an exaggerated disease course both in EAE (Broderick
et al., 2002) and retinal inﬂammation (Hoek et al., 2000).
What remains to be established is the question whether the
CX3CL1-CX3CR1 or CD200-CD200r axes are affected in the dis-
eased brain. To this end, there are only a few reports aboutCXC3L1
levels in the brain and CX3CR1 expression levels in microglia
during the course of disease. For example, Cardona et al. (2006)
detected rather high levels of free CX3CL1 in the brain (around
300pg/mg), which is suggestive of constitutive CX3CL1 release
under normal physiological conditions. In the diseased (rodent or
human) brain, the levels of CX3CL1 and/or CX3CR1 were found
either to be unchanged or increased (Hughes et al., 2002; Tarozzo
et al., 2002; Hulshof et al., 2003; Lindia et al., 2005; Xu et al., 2012),
indicating that the inhibitory function of the CX3CL1-CX3CR1
axis is not generally weakened under diseased conditions. This
might be different in the aged brain or brains of Alzheimer patients
where a downregulationof CX3CL1was recently observed (Wynne
et al., 2010; Cho et al., 2011).
Even less is known about the regulation of CD200 or CD200r
expression in disease. It was reported that in human multiple
sclerosis (MS) patients, CD200 expression in neurons diminishes
around the periphery and in the center of MS lesions (Koning
et al., 2007); however, astrocytes in these lesions acquire CD200
expression (Koning et al., 2009). In a mouse model of hippocam-
pal excitotoxicity, an increase in neuronal CD200 expression was
observed (Yi et al., 2012), while a decrease in CD200 and CD200r
expression was reported in a mouse model of Alzheimer’s disease
(Walker et al., 2009)
Thus, it is at the moment unclear whether CX3CR1 or CD200r
signaling is diminished in the diseased brain. To gain more knowl-
edge about the regulation of the microglia inhibitory environment
during brain disease is, however, of importance for our interpreta-
tion of the results gained in mice with mutated CX3CL1-CX3CR1
or CD200-CD200r signaling. In other words it remains to be
established whether or not in a given brain disease the inhibitory
input for microglia is decreased and as a result these cells become
“hyperactivated” and potentially neurotoxic.
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OTHER MOUSE MODELS WITH MUTATED MICROGLIA
(FUNCTION)
In amyotrophic lateral sclerosis (ALS), mutations within the
ubiquitously expressed enzyme superoxide dismutase 1 (SOD1)
gene are responsible for about a quarter of the inherited dis-
ease cases. Accordingly, mice that express mutant human SOD1
exhibit motoneuron degeneration and a decreased life span (see
for review: Lobsiger and Cleveland, 2007). The role of microglia
in this disease has been investigated in various elegant exper-
iments in which mutated SOD1 was expressed in speciﬁc cell
types (Pramatarova et al., 2001; Lino et al., 2002; Clement et al.,
2003; Beers et al., 2006; Boillée et al., 2006). The conclusion that
arose from these experiments was that microglia with mutated
SOD1 do not initiate motor neuron degeneration but rather
accelerate disease progression (see for review: Lobsiger and Cleve-
land, 2007), since the replacement of SOD1 mutated microglia
with wild-type cells slowed down disease progression and pro-
longed the life span of the animals (Beers et al., 2006); this effect
required functional MyD88 signaling in microglia, indicating
that proper immune function of these cells is necessary in order
to inhibit disease progression and prolong the lifespan of ani-
mals (Kang and Rivest, 2007). Similarly, it was recently reported
that transplantation of wild-type microglia into the brains of
mice deﬁcient for methyl-CpG binding protein (MECP2−/−;
a model for Rett syndrome) ameliorated disease progression
and signiﬁcantly increased the life span of the animals (Derecki
et al., 2012).
MUTATED HUMAN MICROGLIA
Triggering receptor expressed on myeloid cells-2 (TREM2) is
another receptor that is in brain exclusively expressed in microglia
(for review see: Linnartz et al., 2010). TREM2 belongs to the fam-
ily of immunoreceptor tyrosine-based activation motif (ITAM)
receptors for which the ligand has yet not been identiﬁed. Acti-
vation of TREM2 stimulates phagocytic activity in microglia
and downregulates TNFα and inducible nitric oxide synthase
(iNOS) expression (Takahashi et al., 2005). TREM2 is thus an anti-
inﬂammatory receptor that at the same time promotes phagocytic
activity. TREM2 is intracellularly coupled to the adapter protein
DAP12 (see for review: Linnartz et al., 2010), and interestingly,
loss of function mutations of either TREM2 or DAP12 lead to a
rare chronic neurodegenerative disease known as Nasu–Hakola
or polycystic lipomembranous osteodysplasia with sclerosing
leukoencephalopathy (PLOSL), an inherited autosomal recessive
human disease characterized by early onset presenile dementia
(Colonna, 2003).
It can thus be appreciated from the studies discussed in
the last three chapters that milder disease or less neuronal
loss in the presence of mutated microglia is seldom occur-
ring. In contrary, the perturbation of proper microglia function
by various mutations regularly leads to neuronal dysfunction
and/or neurodegeneration, ﬁndings that would not corroborate
the idea that microglia can become neurotoxic cells. It should
be noted that the problem of microglia vs. peripheral mono-
cytes/macrophages, however, also is of importance here since
none of the above described mutated genes is exclusively found in
microglia.
MODELS OF MICROGLIAL INHIBITION OR DEPLETION
MICROGLIA DEPLETION WITH CLODRONATE
The bisphosphonate drug clodronate is toxic to cells of themyeloid
lineage and can be used to selectively deplete them in vivo and
in vitro (Buiting and Van Rooijen, 1994). Since microglia are of
myeloid origin, clodronate can also be used to deplete microglia
in cell culture, organotypic hippocampal slice cultures (OHSC)
and in vivo (Kohl et al., 2003; Lauro et al., 2010; Drabek et al.,
2012). OHSC are in vitro explant cultures that reﬂect many
aspects of the hippocampus in vivo situation by maintaining
a certain degree of intrinsic connectivity and lamination (see
for example: Frotscher et al., 1995). With respect to microglia,
it is known that after 10 days in culture these cells acquire a
ramiﬁed morphology that is comparable to their in vivo coun-
terparts (Hailer et al., 1996). OHSC neurons of the CA1, CA3,
and DG regions display distinct and selective neuronal vulnerabil-
ity towardN-methyl-D-aspartate (NMDA)-induced excitotoxicity,
with CA1 neurons being the most susceptible, followed by CA3
and DG neurons, respectively (Vornov et al., 1991; Cronberg
et al., 2005; Boscia et al., 2006; Gee et al., 2006). Importantly,
this effect has also been observed in vivo (Kirino and Sano,
1984; Horn and Schlote, 1992; Acarin et al., 1996; Won et al.,
1999; Schauwecker, 2002). In addition, there is a strict corre-
lation between the amount of neuronal loss occurring and the
morphological proﬁle of microglia in OHSC subjected to exci-
totoxicity (Heppner et al., 1998; van Weering et al., 2011; Vinet
et al., 2012). We have used OHSC to address the function of
microglia in NMDA-induced neuronal loss by depleting microglia
and then replenishing them with microglia (Vinet et al., 2012).
It was found that neuronal cell loss was prominently increased
in the absence of microglia and that even neurons of the DG
were affected by the NMDA treatment when microglia cells were
not present (Vinet et al., 2012). These ﬁndings are in agreement
with earlier reports from our group, as well as from others (Mon-
tero et al., 2009; van Weering et al., 2011). In addition to earlier
ﬁndings, we also showed that when microglia-free OHSCs were
replenished with microglia, these cells invaded the tissue, dis-
tributed themselves evenly across the slice and acquired an in
vivo-like, ramiﬁed morphology (Vinet et al., 2012). Most impor-
tantly, neurons in the presence of these ectopic microglia were
protected from NMDA-induced toxicity to the same extent as in
non-depleted control slices (Vinet et al., 2012). These ﬁndings
convincingly show not only that microglia have a neuropro-
tective capacity, but also that this property applies to ramiﬁed
microglia (Vinet et al., 2012). Thus, neurons are protected in
the vicinity of ramiﬁed microglia, while removing microglia
from the local environment renders neurons more vulnerable to
excitotoxicity.
Although it is yet not clear whether similar processes also occur
in vivo, it is tempting to speculate that numerous protective prop-
erties of microglia have simply gone unnoticed because ramiﬁed
microglia were generally long considered to be inactive cells. This
speculation is corroborated by recent ﬁndings in the neonatal
brain subjected to middle cerebral artery occlusion (MCAO), a
widely used stroke model. Here it was reported by Faustino et al.
(2011) that the depletion (or reduction) of ramiﬁed microglia
in vivo (by intracerebral injection of clodronate-ﬁlled liposomes)
Frontiers in Cellular Neuroscience www.frontiersin.org May 2013 | Volume 7 | Article 71 | 5
“fncel-07-00071” — 2013/5/20 — 11:49 — page 6 — #6
Hellwig et al. Microglial neurotoxicity revisited
exacerbated injury after stoke. Interestingly, the initial effect of the
MCAO did not change in the absence of microglia, however, the
volume of the lesion gradually increased over time (Faustino et al.,
2011), again suggesting that the absence of ramiﬁed microglia is
detrimental to the injured brain.
CD11b HSVTK MOUSE LINES
Another way to speciﬁcally target microglia is through the use of
transgenic mouse strains in which the herpes simplex virus thymi-
dine kinase (HSVTK) is placed under the control of the CD11b
promoter (Heppner et al., 2005; Gowing et al., 2006). Treating
OHSCs from these animals with ganciclovir efﬁciently depletes
microglia from the tissue slice culture (Falsig et al., 2008; Vinet
et al., 2012). As a result the lack of microglia increases prion titers
by 15 times and thereby also the susceptibility of the slices to prion
infection was enhanced (Falsig et al., 2008). From these results
the authors concluded that microglia are important elements in
containment of prion infections (Falsig et al., 2008).
Application of ganciclovir to CD11b-HSVTK animals leads to
the death of proliferating CD11b+ cells (Heppner et al., 2005;
Gowing et al., 2006). The effects of ganciclovir on microglia in
vivo are dependent on the application route of the drug in these
animals. If peripheral ganciclovir application (intraperitoneal
injection or oral application) is used, transplantation of wild-type
bone-marrow is required to spare the peripheral myeloid com-
partment from ganciclovir treatment. In these resulting chimeric
animals, ganciclovir application leads to the inhibition of mor-
phological microglia transition to amoeboid cells in the case of
EAE (referred to as microglia paralysis Heppner et al., 2005), or
to the death of microglia undergoing proliferation after exper-
imental stroke (Lalancette-Hébert et al., 2007). No effects of
peripheral ganciclovir application on ramiﬁed microglia were
found in these studies (Heppner et al., 2005; Lalancette-Hébert
et al., 2007). Whereas the inhibition of morphological microglia
transition (microglia paralysis) was protective in EAE (delayed
disease onset and reduced clinical scores; Heppner et al., 2005),
the ablation of microglia proliferation in the stroke model led
to a larger stroke lesion area and increased neuronal death
(Lalancette-Hébert et al., 2007).
More recent studies using these mouse lines have changed the
application route of ganciclovir from peripheral to central, which
has a twofold beneﬁt. First, the need for bone-marrow trans-
plantation is circumvented, and second ramiﬁed microglia are
also sensitive to centrally delivered ganciclovir, which depletes the
treated brain tissue of ramiﬁed microglia (Gowing et al., 2008;
Grathwohl et al., 2009; Mirrione et al., 2010; Varvel et al., 2012).
In the corresponding studies it was shown that the depletion of
microglia by ganciclovir did not affect the development of beta
amyloid plaques in two different mouse models of Alzheimer’s
disease (Grathwohl et al., 2009), nor did the absence of microglia
change disease progression and motor neuron degeneration in the
SOD mouse model of ALS (Gowing et al., 2008). However, in the
case of pilocarpine-induced seizures, the depletion of microglia
prevented the protective effect of LPS pre-conditioning, indicat-
ing that the inﬂammatory capacity of microglia is beneﬁcial in
this mouse model (Mirrione et al., 2010). Taken together, it can
be concluded that ganciclovir-dependent inhibition of microglia
function in CD11b-HSVTK animals was only advantageous in a
diseasemodel in one reported case (Heppner et al., 2005). All other
reports either provided evidence for a beneﬁcial role of microglial
function in vivo (Lalancette-Hébert et al., 2007; Mirrione et al.,
2010) or showed no effect of blunting the microglial response
(Gowing et al., 2008; Grathwohl et al., 2009). It should be noted
here that the latter studies inhibited or depleted microglia for a
limited time at rather late stages of chronic disease models (Gow-
ing et al., 2008; Grathwohl et al., 2009), which may explain the
surprising lack of effect. The inhibition or depletion of microglial
function may have been too late or too short to unravel the role
of these cells in mouse models of AD and ALS (Gowing et al.,
2008; Grathwohl et al., 2009). Thus, inhibition or depletion of
microglia for longer time periods may be required for chronic
disease models.
CD11b-DTR MICE
Another mouse model that allows the depletion of myeloid cells is
the CD11b-DTR mouse line that expresses diphtheria toxin recep-
tor under the control of the CD11b promoter (Dufﬁeld et al.,
2005). This mouse was very recently used to study the role of
microglia in the development of the cortex (Ueno et al., 2013).
This study shows that impaired microglia function or depletion of
these cells by diphtheria toxin injection leads to enhancedneuronal
loss of layer V neurons. The authors furthermore provide evi-
dence that microglia provide trophic support for layer V neurons
through the synthesis and release of IGF1. Interestingly, this vital
role of microglia for layer V neurons was attributed to amoeboid
microglia (Ueno et al., 2013).
Taken together, depleting microglia is rarely correlated to
improved outcome in various brain diseasemodels. These ﬁndings
are thus not in favor of amajor neurotoxic function of microglia in
the brain but would argue more for a protective role of the innate
immune cells of the brain.
CONCLUSION
Innate immunity was originally seen as a stereotypic response to
exogenous pathogens. However, the“dangermodel”formulated by
Polly Matzinger more than a decade ago (Matzinger, 2002) couple
with more recent ﬁndings that pattern recognition receptors are
also activated by endogenous ligands [so-called danger-associated
molecular patterns (DAMP)] have dramatically challenged this
original view (Gordon, 2002). Even the classical immune defense
components, such as the complement system, which are activated
to ward off pathogens have now been recognized as danger signals
that are not necessarily linked to pathogen infection (Köhl, 2006).
Moreover, innate immune cells are no longer considered to elicit
a stereotypic response. In striking contrast, it now is apparent
that in the face of different kinds of threats, innate immune cells
are able to interpret signals and launch an appropriate response
(see for review: Gordon, 2003; Martinez et al., 2008; Mosser and
Edwards, 2008; Gordon and Mantovani, 2011). Hence, it is now
clear that tissue damage or cellular stress is also a potent inducer of
innate immunity, where the ultimate goal is to protect and restore
cellular function, thereby guaranteeing the functional integrity
of the body (Medzhitov, 2010). Microglia, the innate immune
cells of the brain, should be viewed along the same lines, because
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infections with exogenous pathogens are (luckily) scarce events
in the brain making cellular stress or tissue damage more likely
signals for microglia.
In this review we argue that amoeboid microglia have a bad
reputation. Based on correlative histological data and corre-
sponding in vitro experiments these cells are often discussed to
be neurotoxic. Moreover, their striking similarity with periph-
eral monocytes/macrophages has blurred our picture concerning
the function of these cells. Microglia colonize the CNS very
early and are sequestered there throughout a lifetime, making
it very likely that these cells have an elaborate repertoire of
brain speciﬁc functions that may not be appropriately taken over
by peripheral monocytes/macrophages (Neumann and Wekerle,
2013). Therefore to discriminatemicroglia fromperipheralmono-
cytes/macrophages and to elucidate the functional spectrum of
microglia in the (healthy and diseased) brain will be a major
challenge.
New mouse models may be helpful here. It was recently shown
that following chemical depletion of microglia (CD11b-HSVTK
mouse) there is a rapid and efﬁcient repopulation of the brain
with CD45 high and CCR2+ blood monocytes, which gradually
engrafted into themicroglia-free tissuewith an overall distribution
and morphology reminiscent (yet different) to that of endogenous
microglia (Varvel et al., 2012). This mouse model thus offers an
opportunity to investigate the question whether or not invaded
monocytes/macrophages can become true brain microglia (Varvel
et al., 2012; Neumann andWekerle, 2013). Other newmousemod-
els may also be helpful to distinguish microglia (function) from
peripheral monocytes macrophages. The double knock-in mouse
expressing red ﬂuorescent protein (RFP) and GFP in the CCR2
and CX3CR1 locus, respectively, allows a reliable discrimination
of both cell types even in tissue sections (Mizutani et al., 2012), and
the newly described CX3CR1creER-line can be utilized to construct
KO or overexpression models that will enable us to investigate
the in vivo functions of receptors, signaltransduction pathways
or inﬂammatory mediators in a microglia speciﬁc context (Yona
et al., 2013; Wolf et al., 2013).
Using such models we may now be able to investigate the over-
all picture of microglia responses, for example in the development
of neuropathic pain. There is compelling evidence that amoeboid
microglia in the spinal cord release brain-derived neurotrophic
factor (BDNF) in response to peripheral nerve lesion,which is cru-
cial for the development of neuropathic pain (Tsuda et al., 2003;
Coull et al., 2005; Ulmann et al., 2008). Accordingly, microglia are
seen as inducers of a pathological pain reaction, again indicating
that their action in response to nervous damage is detrimental
(see for recent review: Tsuda et al., 2013). The whole functional
spectrum of microglia derived BDNF under these circumstances,
however, is not known at the moment. Since BDNF is a neuronal
survival factor it is tempting to speculate that one reason for its
release from microglia is to protect neurons from nerve injury.
It may therefore be of interest to analyze the neuronal fate after
peripheral nerve injury in microglia-speciﬁc BDNF KO animals.
Taken together, mutating or deleting microglia very often leads
to the development or worsening of a brain disease, results that are
favoring a beneﬁcial role of these cells in the CNS. It is discussed
here that several experimental problems around these cells have led
to potential misinterpretations concerning the role of microglia. It
is thus clear that without (i) a detailed analysis of the causal rela-
tionship between microglial function and neuronal fate, and (ii)
a thorough understanding of all aspects of the microglia response
in a given disease (model), it is difﬁcult to fully appreciate what
microglia are doing in the brain. As new techniques and mouse
models are now emerging to do such analysis, it is anticipated that
more surprising ﬁndings about “the brain’s best friend” will be
published.
ACKNOWLEDGMENTS
Knut Biber is supported by the DFG (FOR 1336 “From mono-
cytes to brain macrophages-conditions inﬂuencing the fate of
myeloid cells in the brain”; DFG BI 668/5-1), DFG grant BI 668/2-
2 and BMBF-funded Competence Network Degenerative Diseases
(KNDD). The authors are grateful to Dr. Sandra Dieni for critical
reading and editing.
REFERENCES
Abbadie, C., Lindia, J. A., Cumiskey,
A. M., Peterson, L. B., Mudgett,
J. S., Bayne, E. K., et al. (2003).
Impaired neuropathic pain responses
in mice lacking the chemokine recep-
tor CCR2. Proc. Natl. Acad. Sci.
U.S.A. 100, 7947–7952.
Acarin, L., Gonzalez, B., Castellano, B.,
and Castro, A. J. (1996). Microglial
response to N-methyl-D-aspartate-
mediated excitotoxicity in the imma-
ture rat brain. J. Comp. Neurol. 367,
361–374.
Aguzzi, A., Barres, B. A., and Bennett,
M. L. (2013). Microglia: scapegoat,
saboteur, or something else? Science
339, 156–161.
Ajami, B., Bennett, J. L., Krieger, C.,
McNagny, K. M., and Rossi, F. M.
(2011). Inﬁltrating monocytes trig-
ger EAE progression, but do not
contribute to the resident microglia
pool. Nat. Neurosci. 14, 1142–1149.
Ajami, B., Bennett, J. L., Krieger, C.,
Tetzlaff, W., and Rossi, F. M. (2007).
Local self-renewal can sustain CNS
microglia maintenance and function
throughout adult life. Nat. Neurosci.
10, 1538–1543.
Allan, S. M., Tyrrell, P. J., and Rothwell,
N. J. (2005). Interleukin-1 and neu-
ronal injury. Nat. Rev. Immunol. 5,
629–640.
Alliot, F., Godin, I., and Pessac, B.
(1999). Microglia derive from pro-
genitors, originating from the yolk
sac, and which proliferate in the
brain. Brain Res. Dev. Brain Res. 117,
145–152.
Beers, D. R., Henkel, J. S., Xiao, Q.,
Zhao, W., Wang, J., Yen, A. A., et al.
(2006). Wild-type microglia extend
survival in PU. 1 knockout mice with
familial amyotrophic lateral sclerosis.
Proc. Natl. Acad. Sci. U.S.A. 103,
16021–16026.
Biber, K., Neumann, H., Inoue, K.,
and Boddeke, H. W. (2007). Neu-
ronal ‘On’ and ‘Off ’ signals con-
trol microglia. Trends Neurosci. 30,
596–602.
Blais, V., and Rivest, S. (2004). Effects
of TNF-alpha and IFN-gamma on
nitric oxide-induced neurotoxicity in
the mouse brain. J. Immunol. 172,
7043–7052.
Block, M. L., Zecca, L., and Hong, J.
S. (2007). Microglia-mediated neu-
rotoxicity: uncovering the molecular
mechanisms. Nat. Rev. Neurosci. 8,
57–69.
Boillée, S., Yamanaka, K., Lobsiger, C.
S., Copeland, N. G., Jenkins, N. A.,
Kassiotis, G., et al. (2006). Onset
and progression in inherited ALS
determined by motor neurons and
microglia. Science 312, 1389–1392.
Boje, K. M., and Arora, P. K. (1992).
Microglial-produced nitric oxide and
reactive nitrogen oxidesmediate neu-
ronal cell death. Brain Res. 587,
250–256.
Boscia, F., Annunziato, L., and
Taglialatela, M. (2006). Retigabine
and ﬂupirtine exert neuroprotective
actions in organotypic hippocam-
pal cultures. Neuropharmacology 51,
283–294.
Boucsein, C., Kettenmann, H., and
Nolte, C. (2000). Electrophysiolog-
ical properties of microglial cells
in normal and pathologic rat brain
slices. Eur. J. Neurosci. 12, 2049–2058.
Broderick, C., Hoek, R. M., Forrester,
J. V., Liversidge, J., Sedgwick, J. D.,
and Dick, A. D. (2002). Constitutive
retinal CD200 expression regulates
Frontiers in Cellular Neuroscience www.frontiersin.org May 2013 | Volume 7 | Article 71 | 7
“fncel-07-00071” — 2013/5/20 — 11:49 — page 8 — #8
Hellwig et al. Microglial neurotoxicity revisited
resident microglia and activation
state of inﬂammatory cells during
experimental autoimmune uveore-
tinitis. Am. J. Pathol. 161, 1669–1677.
Buiting, A. M., and Van Rooijen, N.
(1994). Liposome mediated deple-
tion of macrophages: an approach for
fundamental studies. J. Drug Target.
2, 357–362.
Burguillos, M. A., Deierborg, T.,
Kavanagh, E., Persson, A., Hajji, N.,
Garcia-Quintanilla, A., et al. (2011).
Caspase signalling controls microglia
activation and neurotoxicity. Nature
472, 319–324.
Cardona, A. E., Pioro, E. P., Sasse, M.
E., Kostenko, V., Cardona, S. M.,
Dijkstra, I. M., et al. (2006). Con-
trol of microglial neurotoxicity by the
fractalkine receptor. Nat. Neurosci. 9,
917–924.
Chao, C. C., Hu, S., Molitor, T. W.,
Shaskan, E. G., and Peterson, P. K.
(1992). Activated microglia medi-
ate neuronal cell injury via a nitric
oxide mechanism. J. Immunol. 149,
2736–2741.
Cho, S.H., Sun,B., Zhou,Y.,Kauppinen,
T. M., Halabisky, B., Wes, P., et al.
(2011). CX3CR1 protein signaling
modulates microglial activation and
protects against plaque-independent
cognitive deﬁcits in amousemodel of
Alzheimer disease. J. Biol. Chem. 286,
32713–32722.
Cipriani, R., Villa, P., Chece, G., Lauro,
C., Paladini, A., Micotti, E., et al.
(2011). CX3CL1 is neuroprotective
in permanent focal cerebral ischemia
in rodents. J. Neurosci. 31, 16327–
16335.
Clement,A.M.,Nguyen,M.D., Roberts,
E. A., Garcia, M. L., Boillée, S., Rule,
M., et al. (2003). Wild-type nonneu-
ronal cells extend survival of SOD1
mutant motor neurons in ALS mice.
Science 302, 113–117.
Colonna, M. (2003). DAP12 signaling:
from immune cells to bone modeling
and brain myelination. J. Clin. Invest.
111, 313–314.
Colton, C. A. (2009). Heterogene-
ity of microglial activation in the
innate immune response in the
brain. J. Neuroimmune. Pharmacol. 4,
399–418.
Coull, J. A., Beggs, S., Boudreau, D.,
Boivin, D., Tsuda, M., Inoue, K., et al.
(2005). BDNF from microglia causes
the shift in neuronal anion gradient
underlying neuropathic pain. Nature
438, 1017–1021.
Cronberg, T., Jensen, K., Rytter, A., and
Wieloch, T. (2005). Selective sparing
of hippocampal CA3 cells following
in vitro ischemia is due to selec-
tive inhibition by acidosis. Eur. J.
Neurosci. 22, 310–316.
de Haas, A. H., Boddeke, H. W.,
and Biber, K. (2008). Region-
speciﬁc expression of immunoregu-
latory proteins on microglia in the
healthy CNS. Glia 56, 888–894.
de Haas, A. H., Boddeke, H. W.,
Brouwer, N., and Biber, K. (2007).
Optimized isolation enables ex vivo
analysis of microglia from various
central nervous system regions. Glia
55, 1374–1384.
Deng, Y. Y., Lu, J., Ling, E. A., and Kaur,
C. (2009). Monocyte chemoattrac-
tant protein-1 (MCP-1) produced
via NF-kappaB signaling pathway
mediates migration of amoeboid
microglia in the periventricular white
matter in hypoxic neonatal rats. Glia
57, 604–621.
Derecki, N. C., Cronk, J. C., Lu,
Z., Xu, E., Abbott, S. B., Guyenet,
P. G., et al. (2012). Wild-type
microglia arrest pathology in amouse
model of Rett syndrome. Nature 484,
105–109.
Dimitrijevic, O. B., Stamatovic, S. M.,
Keep, R. F., and Andjelkovic, A. V.
(2007). Absence of the chemokine
receptor CCR2 protects against cere-
bral ischemia/reperfusion injury in
mice. Stroke 38, 1345–1353.
Drabek, T., Janata, A., Jackson, E.
K., End, B., Stezoski, J., Vagni,
V. A., et al. (2012). Microglial
depletion using intrahippocampal
injection of liposome-encapsulated
clodronate in prolonged hypother-
mic cardiac arrest in rats. Resuscita-
tion 83, 517–526.
Dufﬁeld, J. S., Forbes, S. J., Constandi-
nou, C. M., Clay, S., Partolina, M.,
Vuthoori, S., et al. (2005). Selec-
tive depletion of macrophages reveals
distinct, opposing roles during liver
injury and repair. J. Clin. Invest. 115,
56–65.
Dunston, C. R., Grifﬁths, H. R., Lam-
bert, P. A., Staddon, S., and Vernal-
lis, A. B. (2011). Proteomic analysis
of the anti-inﬂammatory action of
minocycline. Proteomics 11, 42–51.
El Khoury, J., Toft, M., Hickman, S. E.,
Means, T. K., Terada, K., Geula, C.,
et al. (2007). Ccr2 deﬁciency impairs
microglial accumulation and accel-
erates progression of Alzheimer-like
disease. Nat. Med. 13, 432–438.
Falsig, J., Julius, C., Margalith, I.,
Schwarz, P., Heppner, F. L., and
Aguzzi, A. (2008). A versatile prion
replication assay in organotypic brain
slices. Nat. Neurosci. 11, 109–117.
Fan, L. W., Pang, Y., Lin, S., Rhodes,
P. G., and Cai, Z. (2005). Minocy-
cline attenuates lipopolysaccharide-
induced white matter injury in the
neonatal rat brain. Neuroscience 133,
159–168.
Faustino, J. V., Wang, X., Johnson, C.
E., Klibanov, A., Derugin, N., Wend-
land, M. F., et al. (2011). Microglial
cells contribute to endogenous brain
defenses after acute neonatal focal
stroke. J. Neurosci. 31, 12992–13001.
Fendrick, S. E., Miller, K. R., and
Streit, W. J. (2005). Minocycline does
not inhibit microglia proliferation or
neuronal regeneration in the facial
nucleus following crush injury. Neu-
rosci. Lett. 385, 220–223.
Fernández-López, D., Faustino, J.,
Derugin, N., Wendland, M., Liza-
soain, I., Moro, M. A., et al. (2012).
Reduced infarct size and accumula-
tion of microglia in rats treated with
WIN 55,212-2 after neonatal stroke.
Neuroscience 207, 307–315.
Frotscher,M., Zaﬁrov, S., and Heimrich,
B. (1995). Development of identiﬁed
neuronal types and of speciﬁc synap-
tic connections in slice cultures of rat
hippocampus. Prog. Neurobiol. 45,
vii–xxviii.
Gao, H. M., Zhou, H., Zhang, F., Wil-
son, B. C., Kam, W., and Hong, J.
S. (2011). HMGB1 acts on microglia
Mac1 to mediate chronic neuroin-
ﬂammation that drives progressive
neurodegeneration. J. Neurosci. 31,
1081–1092.
Gee, C. E., Benquet, P., Raineteau, O.,
Rietschin, L., Kirbach, S.W., andGer-
ber, U. (2006). NMDA receptors and
the differential ischemic vulnerabil-
ity of hippocampal neurons. Eur. J.
Neurosci. 23, 2595–2603.
Ginhoux, F., Greter, M., Leboeuf, M.,
Nandi, S., See, P., Gokhan, S.,
et al. (2010). Fate mapping analy-
sis reveals that adult microglia derive
from primitive macrophages. Science
330, 841–845.
Gordon, S. (2002). Pattern recognition
receptors: doubling up for the innate
immune response. Cell 111, 927–930.
Gordon, S. (2003). Alternative acti-
vation of macrophages. Nat. Rev.
Immunol. 3, 23–35.
Gordon, S., and Mantovani, A. (2011).
Diversity and plasticity of mononu-
clear phagocytes. Eur. J. Immunol. 41,
2470–2472.
Gowing, G., Philips, T., Van Wijmeer-
sch, B., Audet, J. N., Dewil, M., Van
Den Bosch, L., et al. (2008). Ablation
of proliferating microglia does not
affect motor neuron degeneration in
amyotrophic lateral sclerosis caused
by mutant superoxide dismutase. J.
Neurosci. 28, 10234–10244.
Gowing, G., Vallières, L., and Julien, J. P.
(2006). Mouse model for ablation of
proliferating microglia in acute CNS
injuries. Glia 53, 331–337.
Graeber, M. B. (2010). Changing face of
microglia. Science 330, 783–788.
Grathwohl, S. A., Kälin, R. E., Bolmont,
T., Prokop, S., Winkelmann, G.,
Kaeser, S. A., et al. (2009). Formation
and “maintenance” of Alzheimer’s
disease beta-amyloid plaques in the
absence of microglia. Nat. Neurosci.
12, 1361–1363.
Hailer, N. P., Jarhult, J. D., and Nitsch,
R. (1996). Resting microglial cells
in vitro: analysis of morphology
and adhesion molecule expression in
organotypic hippocampal slice cul-
tures. Glia 18, 319–331.
Hanisch, U. K., and Kettenmann, H.
(2007). Microglia: active sensor and
versatile effector cells in the normal
and pathologic brain. Nat. Neurosci.
10, 1387–1394.
Hashimoto, K., and Ishima, T. (2010). A
novel target of action of minocycline
in NGF-induced neurite outgrowth
in PC12 cells: translation initia-
tion [corrected] factor eIF4AI. PLoS
ONE 5:e15430. doi: 10.1371/jour-
nal.pone.0015430
He, Y., Appel, S., and Le, W. (2001).
Minocycline inhibits microglial acti-
vation and protects nigral cells after
6-hydroxydopamine injection into
mouse striatum. Brain Res. 909,
187–193.
Heppner, F. L., Greter, M., Marino, D.,
Falsig, J., Raivich,G.,Hövelmeyer,N.,
et al. (2005). Experimental autoim-
mune encephalomyelitis repressed by
microglial paralysis. Nat. Med. 11,
146–152.
Heppner, F. L., Skutella, T., Hailer, N. P.,
Haas, D., and Nitsch, R. (1998). Acti-
vatedmicroglial cellsmigrate towards
sites of excitotoxic neuronal injury
inside organotypic hippocampal slice
cultures. Eur. J. Neurosci. 10, 3284–
3290.
Herbomel, P., Thisse, B., and Thisse, C.
(2001). Zebraﬁsh early macrophages
colonize cephalic mesenchyme and
developing brain, retina, and epi-
dermis through a M-CSF receptor-
dependent invasive process. Dev. Biol.
238, 274–288.
Hoek, R. M., Ruuls, S. R.,Murphy, C. A.,
Wright, G. J., Goddard, R., Zurawski,
S. M., et al. (2000). Down-regulation
of the macrophage lineage through
interaction with OX2 (CD200). Sci-
ence 290, 1768–1771.
Horn, M., and Schlote, W. (1992).
Delayed neuronal death, and delayed
neuronal recovery in the human
brain following global ischemia. Acta
Neuropathol. 85, 79–87.
Huang, W. C., Qiao, Y., Xu, L., Kacimi,
R., Sun, X., Giffard, R. G., et al.
(2010). Direct protection of cultured
neurons from ischemia-like injury
by minocycline. Anat. Cell Biol. 43,
325–331.
Frontiers in Cellular Neuroscience www.frontiersin.org May 2013 | Volume 7 | Article 71 | 8
“fncel-07-00071” — 2013/5/20 — 11:49 — page 9 — #9
Hellwig et al. Microglial neurotoxicity revisited
Hughes, E. H., Schlichtenbrede, F. C.,
Murphy, C. C., Broderick, C., van
Rooijen, N., Ali, R. R., et al. (2004).
Minocycline delays photoreceptor
death in the rds mouse through a
microglia-independent mechanism.
Exp. Eye Res. 78, 1077–1084.
Hughes, P. M., Botham, M. S., Frentzel,
S., Mir, A., and Perry, V. H. (2002).
Expression of fractalkine (CX3CL1)
and its receptor, CX3CR1, during
acute and chronic inﬂammation in
the rodent CNS. Glia 37, 314–327.
Hulshof, S., van Haastert, E. S., Kuipers,
H. F., van den Elsen, P. J., De Groot,
C. J., van der Valk, P., et al. (2003).
CX3CL1 and CX3CR1 expression in
human brain tissue: noninﬂamma-
tory control versus multiple sclero-
sis. J. Neuropathol. Exp. Neurol. 62,
899–907.
Hunter, C. L., Bachman, D., and
Granholm, A. C. (2004). Minocy-
cline prevents cholinergic loss in a
mouse model of Down’s syndrome.
Ann. Neurol. 56, 675–688.
Jung, H., Bhangoo, S., Banisadr, G., Fre-
itag, C., Ren, D., White, F. A., et al.
(2009). Visualization of chemokine
receptor activation in transgenic
mice reveals peripheral activation of
CCR2 receptors in states of neuro-
pathic pain. J. Neurosci. 29, 8051–
8062.
Jung, S., and Schwartz, M. (2012).
Non-identical twins – microglia
and monocyte-derived macrophages
in acute injury and autoimmune
inﬂammation. Front. Immunol. 3:89.
doi: 10.3389/ﬁmmu.2012.00089
Jung, S., Aliberti, J., Graemmel, P.,
Sunshine, M. J., Kreutzberg, G.
W., Sher, A., et al. (2000). Analy-
sis of fractalkine receptor CX(3)CR1
function by targeted deletion and
green ﬂuorescent protein reporter
gene insertion. Mol. Cell. Biol. 20,
4106–4114.
Kang, J., and Rivest, S. (2007). MyD88-
deﬁcient bone marrow cells acceler-
ate onset and reduce survival in a
mouse model of amyotrophic lateral
sclerosis. J. Cell Biol. 179, 1219–1230.
Kettenmann, H., Hanisch, U. K., Noda,
M., andVerkhratsky, A. (2011). Phys-
iology of microglia. Physiol. Rev. 91,
461–553.
Kettenmann, H., Kirchhoff, F., and
Verkhratsky, A. (2013). Microglia:
new roles for the synaptic stripper.
Neuron 77, 10–18.
Kierdorf, K., Erny, D., Goldmann, T.,
Sander, V., Schulz, C., Perdiguero, E.
G., et al. (2013). Microglia emerge
from erythromyeloid precursors
via Pu.1- and Irf8-dependent
pathways. Nat. Neurosci. 16,
273–280.
Kim, S. U., and de Vellis, J. (2005).
Microglia in health and disease. J.
Neurosci. Res. 81, 302–313.
Kim, W. G., Mohney, R. P., Wilson,
B., Jeohn, G. H., Liu, B., and Hong,
J. S. (2000). Regional difference in
susceptibility to lipopolysaccharide-
induced neurotoxicity in the rat
brain: role of microglia. J. Neurosci.
20, 6309–6316.
Kirino, T., and Sano, K. (1984).
Selective vulnerability in the ger-
bil hippocampus following transient
ischemia. Acta Neuropathol. 62,
201–208.
Kohl, A., Dehghani, F., Korf, H. W., and
Hailer, N. P. (2003). The bisphospho-
nate clodronate depletes microglial
cells in excitotoxically injured organ-
otypic hippocampal slice cultures.
Exp. Neurol. 181, 1–11.
Köhl, J. (2006). Self, non-self, and dan-
ger: a complementary view. Adv. Exp.
Med. Biol. 586, 71–94.
Koning, N., Bö, L., Hoek, R. M., and
Huitinga, I. (2007). Downregulation
of macrophage inhibitory molecules
in multiple sclerosis lesions. Ann.
Neurol. 62, 504–514.
Koning, N., Swaab, D. F., Hoek, R.
M., and Huitinga, I. (2009). Dis-
tribution of the immune inhibitory
molecules CD200 and CD200R in
the normal central nervous system
and multiple sclerosis lesions sug-
gests neuron-glia and glia-glia inter-
actions. J. Neuropathol. Exp. Neurol.
68, 159–167.
Kriz, J., Nguyen, M. D., and Julien,
J. P. (2002). Minocycline slows dis-
ease progression in a mouse model of
amyotrophic lateral sclerosis. Neuro-
biol. Dis. 10, 268–278.
Lalancette-Hébert, M., Gowing, G.,
Simard, A., Weng, Y. C., and Kriz,
J. (2007). Selective ablation of pro-
liferating microglial cells exacerbates
ischemic injury in the brain. J. Neu-
rosci. 27, 2596–2605.
Lauro, C., Cipriani, R., Catalano,
M., Trettel, F., Chece, G., Bru-
sadin, V., et al. (2010). Adenosine A1
receptors and microglial cells medi-
ate CX3CL1-induced protection of
hippocampal neurons against Glu-
induced death. Neuropsychopharma-
cology 35, 1550–1559.
Ledeboer, A., Sloane, E. M., Milligan,
E. D., Frank, M. G., Mahony, J. H.,
Maier, S. F., et al. (2005). Minocycline
attenuates mechanical allodynia and
proinﬂammatory cytokine expres-
sion in rat models of pain facilitation.
Pain 115, 71–83.
Lehnardt, S., Schott, E., Trimbuch,
T., Laubisch, D., Krueger, C., Wul-
czyn, G., et al. (2008). A vicious
cycle involving release of heat shock
protein 60 from injured cells and acti-
vation of toll-like receptor 4 medi-
ates neurodegeneration in the CNS.
J. Neurosci. 28, 2320–2331.
Levesque, S., Wilson, B., Gregoria, V.,
Thorpe, L. B., Dallas, S., Polikov, V.
S., et al. (2010). Reactive microglio-
sis: extracellular micro-calpain and
microglia-mediated dopaminergic
neurotoxicity. Brain 133(Pt 3),
808–821.
Lindia, J. A., McGowan, E., Jochnowitz,
N., and Abbadie, C. (2005). Induc-
tion of CX3CL1 expression in astro-
cytes and CX3CR1 in microglia in
the spinal cord of a rat model
of neuropathic pain. J. Pain 6,
434–438.
Linnartz, B., Wang, Y., and Neumann,
H. (2010). Microglial immunore-
ceptor tyrosine-based activation and
inhibition motif signaling in neu-
roinﬂammation. Int. J. Alzheimers
Dis. 2010, pii: 587463.
Lino, M. M., Schneider, C., and Caroni,
P. (2002). Accumulation of SOD1
mutants in postnatal motoneurons
does not cause motoneuron pathol-
ogy or motoneuron disease. J. Neu-
rosci. 22, 4825–4832.
Lobsiger, C. S., and Cleveland, D. W.
(2007). Glial cells as intrinsic compo-
nents of non-cell-autonomous neu-
rodegenerative disease. Nat. Neurosci.
10, 1355–1360.
Martinez, F. O., Sica, A., Mantovani, A.,
and Locati, M. (2008). Macrophage
activation and polarization. Front.
Biosci. 13, 453–461.
Matzinger, P. (2002). An innate sense
of danger. Ann. N. Y. Acad. Sci. 961,
341–342.
Medzhitov, R. (2010). Innate immu-
nity: quo vadis? Nat. Immunol. 11,
551–553.
Melief, J., Koning, N., Schuurman, K.
G., Van De Garde, M. D., Smolders,
J., Hoek, R. M., et al. (2012). Phe-
notyping primary human microglia:
tight regulation of LPS responsive-
ness. Glia 60, 1506–1517.
Mika, J., Osikowicz, M., Makuch, W.,
and Przewlocka, B. (2007). Minocy-
cline and pentoxifylline attenu-
ate allodynia and hyperalgesia and
potentiate the effects of morphine in
rat and mouse models of neuropathic
pain. Eur. J. Pharmacol. 560, 142–149.
Mildner, A., Mack, M., Schmidt, H.,
Brück, W., Djukic, M., Zabel, M. D.,
et al. (2009). CCR2+Ly-6Chi mono-
cytes are crucial for the effector phase
of autoimmunity in the central ner-
vous system. Brain 132(Pt 9), 2487–
2500.
Mildner, A., Schmidt, H., Nitsche,
M., Merkler, D., Hanisch, U. K.,
Mack, M., et al. (2007). Microglia
in the adult brain arise from Ly-
6ChiCCR2+ monocytes only under
deﬁned host conditions. Nat. Neu-
rosci. 10, 1544–1553.
Mirrione, M. M., Konomos, D.
K., Gravanis, I., Dewey, S. L.,
Aguzzi, A., Heppner, F. L., et al.
(2010). Microglial ablation and
lipopolysaccharide preconditioning
affects pilocarpine-induced seizures
in mice. Neurobiol. Dis. 39, 85–97.
Mizutani, M., Pino, P. A., Saederup,
N., Charo, I. F., Ransohoff, R. M.,
and Cardona, A. E. (2012). The
fractalkine receptor but not CCR2 is
present onmicroglia from embryonic
development throughout adulthood.
J. Immunol. 188, 29–36.
Montero Domínguez, M., González, B.,
and Zimmer, J. (2009). Neuroprotec-
tive effects of the anti-inﬂammatory
compound triﬂusal on ischemia-like
neurodegeneration in mouse hip-
pocampal slice cultures occur inde-
pendent of microglia. Exp. Neurol.
218, 11–23.
Montero, M., Gonzalez, B., and
Zimmer, J. (2009). Immunotoxic
depletion of microglia in mouse
hippocampal slice cultures enhances
ischemia-like neurodegeneration.
Brain Res. 1291, 140–152.
Morganti, J. M., Nash, K. R., Grimmig,
B. A., Ranjit, S., Small, B., Bick-
ford, P. C., et al. (2012). The soluble
isoform of CX3CL1 is necessary for
neuroprotection in a mouse model
of Parkinson’s disease. J. Neurosci. 32,
14592–14601.
Mosser, D. M., and Edwards, J. P.
(2008). Exploring the full spectrum
of macrophage activation. Nat. Rev.
Immunol. 8, 958–969.
Nadeau, S., and Rivest, S. (2002).
Endotoxemia prevents the cere-
bral inﬂammatory wave induced
by intraparenchymal lipopolysaccha-
ride injection: role of glucocorti-
coids and CD14. J. Immunol. 169,
3370–3381.
Nadeau, S., and Rivest, S. (2003). Glu-
cocorticoids play a fundamental role
in protecting the brain during innate
immune response. J. Neurosci. 23,
5536–5544.
Neumann, H., and Wekerle, H.
(2013). Brain microglia: watchdogs
with pedigree. Nat. Neurosci. 16,
253–255.
Nimmerjahn, A., Kirchhoff, F., and
Helmchen, F. (2005). Resting
microglial cells are highly dynamic
surveillants of brain parenchyma in
vivo. Science 308, 1314–1318.
O’Callaghan, J. P., Sriram, K., and
Miller, D. B. (2008). Deﬁning “neu-
roinﬂammation”.Ann. N.Y.Acad. Sci.
1139, 318–330.
Frontiers in Cellular Neuroscience www.frontiersin.org May 2013 | Volume 7 | Article 71 | 9
“fncel-07-00071” — 2013/5/20 — 11:49 — page 10 — #10
Hellwig et al. Microglial neurotoxicity revisited
Olah, M., Amor, S., Brouwer, N., Vinet,
J., Eggen, B., Biber, K., et al. (2012).
Identiﬁcation of a microglia phe-
notype supportive of remyelination.
Glia 60, 306–321.
Osikowicz, M., Skup, M., Mika, J.,
Makuch, W., Czarkowska-Bauch, J.,
and Przewlocka, B. (2009). Glial
inhibitors inﬂuence the mRNA and
protein levels of mGlu2/3, 5, and 7
receptors and potentiate the analgesic
effects of their ligands in a mouse
model of neuropathic pain. Pain 147,
175–186.
Ossola, B., Lantto, T. A., Puttonen,
K. A., Tuominen, R. K., Raasmaja,
A., and Männistö, P. T. (2012).
Minocycline protects SH-SY5Y cells
from 6-hydroxydopamine by inhibit-
ing both caspase-dependent and -
independent programmed cell death.
J. Neurosci. Res. 90, 682–690.
Pabon, M. M., Bachstetter, A. D., Hud-
son, C. E., Gemma, C., and Bickford,
P. C. (2011). CX3CL1 reduces neuro-
toxicity and microglial activation in
a rat model of Parkinson’s disease. J.
Neuroinﬂammation 8, 9.
Pais, T. F., Figueiredo, C., Peixoto, R.,
Braz,M.H., andChatterjee, S. (2008).
Necrotic neurons enhance microglial
neurotoxicity through induction of
glutaminase by a MyD88-dependent
pathway. J. Neuroinﬂammation 5, 43.
Paolicelli, R. C., Bolasco, G., Pagani, F.,
Maggi, L., Scianni, M., Panzanelli,
P., et al. (2011). Synaptic pruning
by microglia is necessary for nor-
mal brain development. Science 333,
1456–1458.
Parkhurst, C. N., and Gan,W. B. (2010).
Microglia dynamics and function in
the CNS. Curr. Opin. Neurobiol. 20,
595–600.
Polazzi, E., and Monti, B. (2010).
Microglia and neuroprotection: from
in vitro studies to therapeutic
applications. Prog. Neurobiol. 92,
293–315.
Pramatarova, A., Laganière, J., Rous-
sel, J., Brisebois, K., and Rouleau,
G. A. (2001). Neuron-speciﬁc expres-
sion of mutant superoxide dismutase
1 in transgenic mice does not lead to
motor impairment. J. Neurosci. 21,
3369–3374.
Prinz, M., and Mildner, A. (2011).
Microglia in the CNS: immigrants
from another world. Glia 59,
177–187.
Prinz, M., and Priller, J. (2010). Tick-
ets to the brain: role of CCR2
and CX3CR1 in myeloid cell entry
in the CNS. J. Neuroimmunol 224,
80–84.
Prinz, M., Priller, J., Sisodia, S.
S., and Ransohoff, R. M. (2011).
Heterogeneity of CNS myeloid cells
and their roles in neurodegeneration.
Nat. Neurosci. 14, 1227–1235.
Raber, J., Allen, A. R., Rosi, S.,
Sharma, S., Dayger, C., Davis, M.
J., et al. (2013). Effects of 56Fe radi-
ation on hippocampal function in
mice deﬁcient in chemokine recep-
tor 2 (CCR2). Behav. Brain Res. 246,
69–75.
Raghavendra, V., Tanga, F., and DeLeo,
J. A. (2003). Inhibition of microglial
activation attenuates the develop-
ment but not existing hypersensitiv-
ity in a rat model of neuropathy.
J. Pharmacol. Exp. Ther. 306,
624–630.
Ransohoff, R. M., and Cardona, A.
E. (2010). The myeloid cells of the
central nervous system parenchyma.
Nature 468, 253–262.
Ransohoff, R. M., and Perry, V.
H. (2009). Microglial physiology:
unique stimuli, specialized responses.
Annu. Rev. Immunol. 27, 119–145.
Ransohoff, R. M., and Prinz, M. (2013).
Editors’preface: microglia – a new era
dawns. Glia 61, 1–2.
Remington, L. T., Babcock,A.A., Zehnt-
ner, S. P., and Owens, T. (2007).
Microglial recruitment, activation,
and proliferation in response to pri-
mary demyelination. Am. J. Pathol.
170, 1713–1724.
Saederup, N., Cardona, A. E., Croft,
K., Mizutani, M., Cotleur, A. C.,
Tsou, C. L., et al. (2010). Selective
chemokine receptor usage by cen-
tral nervous system myeloid cells in
CCR2-red ﬂuorescent protein knock-
in mice. PLoS ONE 5:e13693. doi:
10.1371/journal.pone.0013693
Schafer, D. P., Lehrman, E. K., Kautz-
man, A. G., Koyama, R., Mardinly,
A. R., Yamasaki, R., et al. (2012).
Microglia sculpt postnatal neural cir-
cuits in an activity and complement-
dependent manner. Neuron 74,
691–705.
Schauwecker, P. E. (2002). Modula-
tion of cell death by mouse genotype:
differential vulnerability to excita-
tory amino acid-induced lesions. Exp.
Neurol. 178, 219–235.
Schildknecht, S., Pape, R., Müller, N.,
Robotta, M., Marquardt, A., Bürkle,
A., et al. (2011). Neuroprotection by
minocycline causedbydirect and spe-
ciﬁc scavenging of peroxynitrite. J.
Biol. Chem. 286, 4991–5002.
Schilling, M., Strecker, J. K., Ringelstein,
E. B., Schäbitz, W. R., and Kiefer, R.
(2009a). The role of CC chemokine
receptor 2 on microglia activation
and blood-borne cell recruitment
after transient focal cerebral ischemia
in mice. Brain Res. 1289, 79–84.
Schilling, M., Strecker, J. K., Schäb-
itz, W. R., Ringelstein, E. B., and
Kiefer, R. (2009b). Effects of mono-
cyte chemoattractant protein 1 on
blood-borne cell recruitment after
transient focal cerebral ischemia in
mice. Neuroscience 161, 806–812.
Schmid, C. D., Melchior, B., Masek,
K., Puntambekar, S. S., Daniel-
son, P. E., Lo, D. D., et al.
(2009). Differential gene expres-
sion in LPS/IFNgamma activated
microglia, and macrophages: in
vitro versus in vivo. J. Neurochem.
109(Suppl. 1), 117–125.
Sedgwick, J. D., Ford, A. L., Foulcher, E.,
and Airriess, R. (1998). Central ner-
vous system microglial cell activation
and proliferation follows direct inter-
action with tissue-inﬁltrating T cell
blasts. J. Immunol. 160, 5320–5330.
Sierra, A., Encinas, J. M., Deudero,
J. J., Chancey, J. H., Enikolopov,
G., Overstreet-Wadiche, L. S.,
et al. (2010). Microglia shape adult
hippocampal neurogenesis through
apoptosis-coupled phagocytosis. Cell
Stem Cell 7, 483–495.
Sorokin, S. P., Hoyt, R. F. Jr., Blunt,
D. G., and McNelly, N. A. (1992).
Macrophage development: II. Early
ontogeny of macrophage popula-
tions in brain, liver, and lungs of
rat embryos as revealed by a lectin
marker. Anat. Rec. 232, 527–550.
Szeto, G. L., Pomerantz, J. L., Graham,
D. R., and Clements, J. E. (2011).
Minocycline suppresses activation of
nuclear factor of activated T cells 1
(NFAT1) in human CD4+ T cells. J.
Biol. Chem. 286, 11275–11282.
Takahashi, K., Rochford, C. D.,
and Neumann, H. (2005). Clear-
ance of apoptotic neurons without
inﬂammation by microglial trigger-
ing receptor expressed on myeloid
cells-2. J. Exp. Med. 201, 647–657.
Tarozzo, G., Campanella, M., Ghiani,
M., Bulfone, A., and Beltramo, M.
(2002). Expression of fractalkine, and
its receptor, CX3CR1, in response to
ischaemia-reperfusionbrain injury in
the rat. Eur. J. Neurosci. 15, 1663–
1668.
Tikka, T., Fiebich, B. L., Goldsteins,
G., Keinanen, R., and Koistinaho, J.
(2001). Minocycline, a tetracycline
derivative, is neuroprotective against
excitotoxicity by inhibiting activa-
tion and proliferation of microglia. J.
Neurosci. 21, 2580–2588.
Tremblay, M. È., Lowery, R. L., and
Majewska, A. K. (2010). Microglial
interactions with synapses are mod-
ulated by visual experience. PLoS
Biol. 8:e1000527. doi: 10.1371/jour-
nal.pbio.1000527
Tremblay, M. È., Stevens, B., Sierra, A.,
Wake, H., Bessis, A., and Nimmer-
jahn, A. (2011). The role of microglia
in the healthy brain. J. Neurosci. 31,
16064–16069.
Tsuda, M., Shigemoto-Mogami, Y.,
Koizumi, S., Mizokoshi, A., Kohsaka,
S., Salter, M. W., et al. (2003).
P2X4 receptors induced in spinal
microglia gate tactile allodynia after
nerve injury. Nature 424, 778–783.
Tsuda, M., Beggs, S., Salter, M. W.,
and Inoue, K. (2013). Microglia and
intractable chronic pain. Glia 61,
55–61.
Ueno, M., Fujita, Y., Tanaka, T., Naka-
mura, Y., Kikuta, J., Ishii, M., et al.
(2013). Layer V cortical neurons
require microglial support for sur-
vival during postnatal development.
Nat. Neurosci. 16, 543–551.
Ulmann, L., Hatcher, J. P., Hughes, J.
P., Chaumont, S., Green, P. J., Con-
quet, F., et al. (2008). Up-regulation
of P2X4 receptors in spinal microglia
after peripheral nerve injurymediates
BDNF release and neuropathic pain.
J. Neurosci. 28, 11263–11268.
van Weering, H. R., Boddeke, H.
W., Vinet, J., Brouwer, N., de
Haas, A. H., van Rooijen, N., et al.
(2011). CXCL10/CXCR3 signaling in
glia cells differentially affects NMDA-
induced cell death in CA and DG
neurons of the mouse hippocampus.
Hippocampus 21, 220–232.
Varvel, N. H., Grathwohl, S. A., Bau-
mann, F., Liebig, C., Bosch, A.,
Brawek, B., et al. (2012). Microglial
repopulation model reveals a robust
homeostatic process for replacing
CNS myeloid cells. Proc. Natl.
Acad. Sci. U.S.A. 109, 18150–
18155.
Vinet, J., Weering, H. R., Heinrich, A.,
Kälin, R. E., Wegner, A., Brouwer,
N., et al. (2012). Neuroprotective
function for ramiﬁed microglia in
hippocampal excitotoxicity. J. Neu-
roinﬂammation 9, 27.
Vornov, J. J., Tasker, R. C., and Coyle,
J. T. (1991). Direct observation of
the agonist-speciﬁc regional vulner-
ability to glutamate, NMDA, and
kainate neurotoxicity in organotypic
hippocampal cultures. Exp. Neurol.
114, 11–22.
Wake, H., Moorhouse, A. J., Jinno, S.,
Kohsaka, S., and Nabekura, J. (2009).
Resting microglia directly monitor
the functional state of synapses in
vivo and determine the fate of
ischemic terminals. J. Neurosci. 29,
3974–3980.
Walker, D. G., Dalsing-Hernandez, J. E.,
Campbell,N.A., andLue, L. F. (2009).
Decreased expression of CD200 and
CD200 receptor in Alzheimer’s dis-
ease: a potential mechanism lead-
ing to chronic inﬂammation. Exp.
Neurol. 215, 5–19.
Frontiers in Cellular Neuroscience www.frontiersin.org May 2013 | Volume 7 | Article 71 | 10
“fncel-07-00071” — 2013/5/20 — 11:49 — page 11 — #11
Hellwig et al. Microglial neurotoxicity revisited
Walker, D. G., and Lue, L. F. (2005).
Investigations with cultured human
microglia on pathogenicmechanisms
of Alzheimer’s disease and other neu-
rodegenerative diseases. J. Neurosci.
Res. 81, 412–425.
Wolf, Y., Yona, S., Kim, K. W., and Jung,
S. (2013). Microglia, seen from the
CX3CR1 angle. Front. Cell. Neurosci.
7:26. doi: 10.3389/fncel.2013.00026
Won, S. J., Ko, H. W., Kim, E.
Y., Park, E. C., Huh, K., Jung,
N. P., et al. (1999). Nuclear fac-
tor kappa B-mediated kainate neu-
rotoxicity in the rat and ham-
ster hippocampus. Neuroscience 94,
83–91.
Wynne, A. M., Henry, C. J., Huang,
Y., Cleland, A., and Godbout, J.
P. (2010). Protracted downregula-
tion of CX3CR1 on microglia of
aged mice after lipopolysaccharide
challenge. Brain Behav. Immun. 24,
1190–1201.
Xie, Z., Smith, C. J., and Van Eldik, L. J.
(2004). Activated glia induce neuron
death via MAP kinase signaling path-
ways involving JNK and p38. Glia 45,
170–179.
Xu, Y., Zeng, K., Han, Y., Wang, L.,
Chen, D., Xi, Z., et al. (2012). Altered
expression of CX3CL1 in patients
with epilepsy and in a rat model. Am.
J. Pathol. 180, 1950–1962.
Yao, Y., and Tsirka, S. E. (2012).
The CCL2-CCR2 system affects
the progression and clearance of
intracerebral hemorrhage. Glia 60,
908–918.
Yi, M. H., Zhang, E., Kang, J. W., Shin,
Y. N., Byun, J. Y., Oh, S. H., et al.
(2012). Expression of CD200 in alter-
native activation of microglia follow-
ing an excitotoxic lesion in the mouse
hippocampus. Brain Res. 1481,
90–96.
Yona, S., Kim, K. W., Wolf, Y., Mild-
ner, A., Varol, D., Breker, M., et al.
(2013). Fate mapping reveals origins
and dynamics of monocytes and tis-
sue macrophages under homeostasis.
Immunity 38, 79–91.
Yong, V. W., and Rivest, S. (2009).
Taking advantage of the sys-
temic immune system to cure
brain diseases. Neuron 64,
55–60.
Yrjänheikki, J., Keinänen, R., Pel-
likka, M., Hökfelt, T., and Koisti-
naho, J. (1998). Tetracyclines inhibit
microglial activation, and are neuro-
protective in global brain ischemia.
Proc. Natl. Acad. Sci. U.S.A. 95,
15769–15774.
Zhang, J., Shi, X. Q., Echeverry, S.,
Mogil, J. S., De Koninck, Y., and
Rivest, S. (2007). Expression of CCR2
in both resident and bone marrow-
derived microglia plays a critical role
in neuropathic pain. J. Neurosci. 27,
12396–12406.
Zuurman, M. W., Heeroma, J., Brouwer,
N., Boddeke, H. W., and Biber,
K. (2003). LPS-induced expres-
sion of a novel chemokine recep-
tor (L-CCR) in mouse glial cells
in vitro and in vivo. Glia 41,
327–336.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 23 January 2013; accepted: 26
April 2013; published online: 16 May
2013.
Citation: Hellwig S, Heinrich A and
Biber K (2013) The brain’s best friend:
microglial neurotoxicity revisited. Front.
Cell. Neurosci. 7:71. doi: 10.3389/fncel.
2013.00071
Copyright © 2013 Hellwig, Heinrich
and Biber. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are
credited and subject to any copyright
notices concerning any third-party graph-
ics etc.
Frontiers in Cellular Neuroscience www.frontiersin.org May 2013 | Volume 7 | Article 71 | 11
